Bio-Path (NASDAQ:BPTH) issued its earnings results on Thursday. The company reported ($0.80) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.83) by $0.03, MarketWatch Earnings reports.

Shares of NASDAQ BPTH opened at $3.67 on Friday. The stock has a market cap of $16.67 million, a PE ratio of -1.24 and a beta of 2.24. Bio-Path has a fifty-two week low of $2.92 and a fifty-two week high of $11.78. The stock has a fifty day moving average of $3.84 and a 200-day moving average of $4.63.

Several brokerages have issued reports on BPTH. HC Wainwright lowered their target price on Bio-Path from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday, November 16th. Zacks Investment Research lowered Bio-Path from a “buy” rating to a “hold” rating in a research note on Monday, October 19th.

About Bio-Path

Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.

See Also: Consumer Price Index (CPI)

Earnings History for Bio-Path (NASDAQ:BPTH)

Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with's FREE daily email newsletter.